摘要
目的:分析非小细胞肺癌患者外周血表皮生长因子受体(EGFR)基因突变检测的临床意义。方法:选择2021年1—12月于武威肿瘤医院就诊的63例非小细胞肺癌患者的数据进行回顾性分析。按照EGFR基因突变类型将其分为EGFR基因突变型组(n=28)、EGFR基因野生型组(n=35)。对比两组一般资料、治疗1个月后的临床效果及预后(无进展生存期),分析患者无进展生存期的影响因素。结果:两组吸烟史、病理类型比例对比,差异均有统计学意义(P<0.05)。EGFR基因突变型患者的疾病缓解率及疾病控制率均高于EGFR基因野生型患者(P<0.05)。EGFR基因突变型组无进展生存期中位数为10.354个月,EGFR基因野生型组无进展生存期中位数为9.212个月,两组无进展生存期曲线对比,差异有统计学意义(log-rank X^(2)=4.027,P<0.05)。年龄、吸烟史、病理类型、是否出现EGFR基因突变是患者无进展生存期的影响因素(RR=3.799、4.297、5.959、7.729,P<0.05)。结论:晚期非小细胞肺癌患者的外周血EFGR基因突变检测对于患者随后的治疗方案选择及生存状态评估具有重要的意义。
Objective:To analyze the clinical significance of epidermal growth factor receptor(EGFR)gene mutation detection in peripheral blood of patients with non-small cell lung cancer.Method:The data of 63 patients with non-small cell lung cancer treated in Wuwei Tumour Hospital from January to December 2021 were selected for retrospective analysis.They were divided into EGFR gene mutation group(n=28)and EGFR gene wild type(n=35).The general data,clinical effect after 1 month of treatment and prognosis(progression free survival)were compared between the two groups,and the influencing factors of progression free survival were analyzed.Result:There were statistically significant differences in the proportions of smoking history and pathological types between the two groups(P<0.05).The disease remission rate and disease control rate of EGFR gene mutation patients were higher than those of EGFR gene wild type patients(P<0.05).The median progression free survival was 10.354 months in the EGFR gene mutation group and 9.212 months in the EGFR gene wild type group.The difference in the progression free survival curve between the two groups was statistically significant(log-rankX^(2)=4.027,P<0.05).Age,smoking history,pathologic type and presence or absence of EGFR gene mutation were the influencing factors for progression free survival(RR=3.799,4.297,5.959,7.729,P<0.05).Conclusion:Detection of EFGR gene mutation in peripheral blood of patients with advanced non-small cell lung cancer is of great significance for subsequent treatment selection and survival status assessment of patients.
作者
曾多
王晓梅
李正国
赵丽
ZENG Duo;WANG Xiaomei;LI Zhengguo;ZHAO Li(Wuwei Tumour Hospital,Gansu Province,Wuwei 733099,China;不详)
出处
《中国医学创新》
CAS
2023年第24期19-23,共5页
Medical Innovation of China
基金
武威市科技局基金资助项目(ww2002062)。
关键词
非小细胞肺癌
外周血
基因突变
靶向治疗
Non-small cell lung cancer
Peripheral blood
Gene mutation
Targeted therapy
